Patient blood management and patient safety

Curr Opin Anaesthesiol. 2022 Dec 1;35(6):733-737. doi: 10.1097/ACO.0000000000001196. Epub 2022 Oct 4.


Purpose of review: The particular fields within patient blood management (PBM) and patient safety reviewed here include novel insights into bleeding therapy, autologous cell salvage, and perioperative anemia therapy.

Recent finding: World Health Organization has published that implementation of PBM is important but has not yet been performed in all hospitals. Two antibodies that mimic the function of FVIII, Emicizumab, and Mim8 have been developed. Tranexamic acid (TXA) has been investigated further in patients with hip surgery and shows reduction of bleeding. Thrombocytopenia in patients undergoing cardiac surgery is a particular concern that has been investigated in another trial. The use of autologous cell salvage was updated in form of a review and meta-analysis. And last but not least, intravenous iron in preoperative anemia therapy can reduce the number of transfusions, but especially iron carboxymaltose can cause hypophosphatemia.

Summary: PBM should be further implemented in more hospitals. Emicizumab and Mim8 are indicated in acquired hemophilia or hemophilia A with inhibitors. TXA was confirmed to reduce bleeding. Autologous cell salvage is state of the art to reduce transfusion requirements in major cardiac and noncardiac surgery. Serum phosphate concentrations should be monitored after administration of intravenous iron compounds.

Publication types

  • Review
  • Meta-Analysis

MeSH terms

  • Anemia* / prevention & control
  • Antifibrinolytic Agents / therapeutic use
  • Blood Loss, Surgical* / prevention & control
  • Humans
  • Patient Safety
  • Tranexamic Acid* / therapeutic use


  • Antifibrinolytic Agents
  • Tranexamic Acid